- Home
- AGI vs LEGN Comparison
AGI vs LEGN Comparison
Compare AGI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGI
- LEGN
- Stock Information
- Founded
- AGI 2003
- LEGN 2014
- Country
- AGI Canada
- LEGN United States
- Employees
- AGI N/A
- LEGN N/A
- Industry
- AGI Precious Metals
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- AGI Basic Materials
- LEGN Health Care
- Exchange
- AGI Nasdaq
- LEGN Nasdaq
- Market Cap
- AGI 10.8B
- LEGN 7.0B
- IPO Year
- AGI 1999
- LEGN 2020
- Fundamental
- Price
- AGI $27.05
- LEGN $31.78
- Analyst Decision
- AGI Buy
- LEGN Strong Buy
- Analyst Count
- AGI 4
- LEGN 13
- Target Price
- AGI $30.38
- LEGN $79.42
- AVG Volume (30 Days)
- AGI 4.4M
- LEGN 1.5M
- Earning Date
- AGI 04-30-2025
- LEGN 05-13-2025
- Dividend Yield
- AGI 0.37%
- LEGN N/A
- EPS Growth
- AGI 19.70
- LEGN N/A
- EPS
- AGI 0.62
- LEGN N/A
- Revenue
- AGI $1,402,300,000.00
- LEGN $627,241,000.00
- Revenue This Year
- AGI $26.44
- LEGN $65.96
- Revenue Next Year
- AGI $10.10
- LEGN $52.55
- P/E Ratio
- AGI $44.22
- LEGN N/A
- Revenue Growth
- AGI 33.63
- LEGN 119.97
- 52 Week Low
- AGI $15.01
- LEGN $29.27
- 52 Week High
- AGI $31.00
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- AGI 50.04
- LEGN 41.49
- Support Level
- AGI $26.41
- LEGN $30.25
- Resistance Level
- AGI $27.29
- LEGN $35.81
- Average True Range (ATR)
- AGI 0.97
- LEGN 1.45
- MACD
- AGI -0.26
- LEGN -0.18
- Stochastic Oscillator
- AGI 53.41
- LEGN 27.58
About AGI Alamos Gold Inc.
Alamos Gold Inc acquires, explores, and produces gold and other precious metals, and operates in two principal geographic areas: Canada and Mexico. The company has four operating segments being Young-Davidson, Island Gold and Magino mines operate in Canada, and the Mulatos mine operates in Sonora, Mexico. The company generates maximum revenue from the Mulatos mines.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.